Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buspirone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buspirone SCHEMBL17004050 | 1.00 | HTR1A (1.00) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| Buspirone SCHEMBL41496 | 0.99 | HTR1A (0.98) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| Buspirone SCHEMBL10441318 | 0.99 | ALDH1A1 (1.00) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| SCHEMBL11875965 | 0.99 | HTR1A (0.98) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| SCHEMBL11875345 | 0.99 | HTR1A (0.98) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| Buspirone SCHEMBL41495 | 0.99 | ALDH1A1 (1.00) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| Hydrochloric Acid SCHEMBL11880141 | 0.98 | ALDH1A1 (0.98) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| Hydrochloric Acid SCHEMBL11878911 | 0.98 | ALDH1A1 (0.98) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| SCHEMBL11881209 | 0.97 | HTR1A (0.95) | HTR1AALDH1A1DRD2HTR2ASLC22A2 | |
| Hydrochloric Acid SCHEMBL11877578 | 0.96 | ALDH1A1 (0.95) | HTR1AALDH1A1DRD2HTR2ASLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25197 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260092932-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER | THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) | 2026-04-02 | — | — | US | claimed |
| EP-4712996-A1 | HIP/PAP PROTEIN OR A DERIVATIVE THEREOF FOR TREATING A COGNITIVE DISORDER ASSOCIATED WITH ANXIETY DISORDER | THE HEALTHY AGING COMPANY (FR) | 2026-03-25 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4678628-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS | Connecta Theapeutics, S.L. (ES) | 2026-01-14 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| EP-0276543-A2 | Use of buspirone for the improvement of short term memory | Bristol-Myers Squibb Company (US) | 1988-08-03 | — | — | EP | claimed |
| US-4687772-A | Method for improvement of short term memory | BRISTOL-MYERS COMPANY (US) | 1987-08-18 | — | — | US | claimed |
| WO-1987004621-A1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BUSPIRONE | OTHMER EKKEHARD (US) | 1987-08-13 | — | — | WO | claimed |
| EP-0220696-A2 | Use of buspirone for preparing pharmaceutical compositions for alleviation of phobic anxiety | Bristol-Myers Squibb Company (US) | 1987-05-06 | — | — | EP | claimed |
| US-4640921-A | GENERALIZED ANXIETY DISORDER | BRISTOL-MYERS (US) | 1987-02-03 | — | — | US | claimed |
| US-4634703-A | Method for alleviation of panic disorders | BRISTOL-MYERS COMPANY (US) | 1987-01-06 | — | — | US | claimed |
| US-4438119-A | BUSPIRONE OR SALTS THEREOF | MEAD JOHNSON & COMPANY (US) | 1984-03-20 | — | — | US | claimed |
| US-4351939-A | Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process | MEAD JOHNSON & COMPANY (US) | 1982-09-28 | — | — | US | claimed |
| US-4182763-A | PALLIATIVE TREATMENT OF NEUROSES | MEAD JOHNSON & COMPANY (US) | 1980-01-08 | — | — | US | claimed |
| US-3976776-A | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones | MEAD JOHNSON & COMPANY (US) | 1976-08-24 | — | — | US | claimed |